Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib plus EP/EC chemotherapy for first-line extensive-stage small cell lung cancer
ChiCTR2300071984Phase 4Not yet recruiting
- Sponsor
- Jingzhou Central Hospital
- Start
- May 2023
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of surufatinib, etoposide, cisplatin and carboplatin in small cell lung cancer (SCLC), sponsored by Jingzhou Central Hospital. Primary endpoint: Progression-free survival. Planned start May 2023; status: not yet recruiting.
02
Drugs
surufatinibetoposidecisplatincarboplatin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2300071984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071984.